Chicago, Illinois 60612


Purpose:

Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.


Criteria:

Inclusion Criteria: - Any adult patient starting capecitabine-containing chemotherapy - Has never had capecitabine before - Performance status 0-2 using the ECOG classification - Life expectancy more than 6 months - Agreed to stop any vitamin supplements, apart from vitamin D. - Liver function studies including AST/ALT within 3x upper limit of normal - Signed informed consent must be obtained from participating individuals


NCT ID:

NCT00767689


Primary Contact:

Tareq Braik, MD
Phone: 312-8390060
Email: tareqbk410@hotmail.com


Backup Contact:

N/A


Location Contact:

Chicago, Illinois 60612
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.